Andromeda diabetes phase III trial successful
If treatment – designed to stop or inhibit disease – is approved for sale, Clal Industries' subsidiary will tap into vast market with no competition
Andromeda is a second tier subsidiary of Clal Industries, which belongs to the IDB group. The company is currently developing a revolutionary treatment which is the first of its kind to stop or at least inhibit diabetes type 1.
If the drug is approved for sale, the company will have tapped into a vast market in which it will face no competition.
The phase III trial was completed two years after the company gained the Food and Drug Administration's approval for the development plan of its flagship drug.
At that time, the FDA also gave Andromeda the green light for the phase III trial, the results of which the company published today.
At the same time, Andromeda is preparing for a validation study of the drug which will include 450 patients in 120 medical centers in the US, Europe, South America and Israel.
Participant recruitment for the validation study is expected to end in the second quarter of 2012.
Shoham Levi contributed to this report
Click here to read this report in Hebrew
